CD19 and diffuse large B-cell lymphoma: Three different constructs of CD19 chimeric antigen receptor T cells (CAR T-cells)—axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)—have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of R/R DLBCL following two or more lines of systemic therapy, showing high response rates [9,10,11].